Targeted therapy is also an important component of lung cancer treatment, and treatment regimens require testing for EGFR, ALK, ROS1, RET, MET, BRAF, NTRK, HER2, NRG1, FGFR1, and PIK3CA (Guo et al., 2019; Wei et al., 2023). This evidence concerns the gene ALK and lung cancer.